Numerous clinical trials spanning Phase 1 through Phase 4 evaluate selinexor across various oncological conditions, including relapsed/refractory multiple myeloma, acute myeloid leukemia, diffuse large B-cell lymphoma, central nervous system lymphoma, sarcomas, endometrial cancer, and pediatric rhabdoid tumors. Sponsored by academic research institutions, children's hospitals, and pharmaceutical organizations such as Karyopharm Therapeutics, Antengene Corporation, and AbbVie, these studies encompass actively recruiting, completed, active not recruiting, and withdrawn statuses. This body of research highlights the compound's evaluation as both a single agent and in multi-drug combination regimens.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06239272 | RECRUITING | Adipocytic Neoplasm; Liposarcoma; Atypical Fibroxanthoma; Angiomatoid Fibrous Histiocytoma; Fibrosarcoma NOS; Myxofibrosarcoma; Angiosarcoma; Osteosarcoma, Extraskeletal; Dedifferentiated Liposarcoma; Myxoid Liposarcoma; Pleomorphic Liposarcoma; Myxoid Pleomorphic Liposarcoma; Low Grade Fibromyxoid Sarcoma; Sclerosing Epithelioid Fibrosarcoma; Malignant Tenosynovial Giant Cell Tumor of Soft Tissue; Epithelioid Hemangioendothelioma; Glomus Tumor; Inflammatory Leiomyosarcoma; Leiomyosarcoma; Ossifying Fibromyxoid Tumor, Malignant; Myoepithelioma; Synovial Sarcoma; Epithelioid Sarcoma; Perineurioma, Malignant; Clear Cell Sarcoma; Extraskeletal Myxoid Chondrosarcoma; Granular Cell Tumor, Malignant; Melanotic Malignant Nerve Sheath Tumor; Malignant Peripheral Nerve Sheath Tumor; Perivascular Epithelioid Tumor, Malignant; Intimal Sarcoma; Myoepithelial Carcinoma; Undifferentiated Sarcoma; Pleomorphic Sarcoma, Undifferentiated; Round Cell Sarcoma, Undifferentiated; NTRK-Rearranged Spindle Cell Neoplasm; Phosphaturic Mesenchymal Tumor, Malignant; Round Cell Sarcoma; Well Differentiated Liposarcoma; Giant Cell Tumor of Soft Parts NOS; Low Grade Myofibroblastic Sarcoma; Dermatofibrosarcoma Protuberans, Fibrosarcomatous |
St. Jude Children's Research Hospital |
2024-03-27 | PHASE1; PHASE2 |
| NCT05983276 | RECRUITING | Ovarian Cancer |
Loyola University |
2023-11-16 | PHASE2 |
| NCT07447817 | NOT_YET_RECRUITING | Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis |
John Mascarenhas |
2026-05-04 | PHASE2 |
| NCT07276698 | NOT_YET_RECRUITING | NK T-Cell Lymphoma |
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine |
2025-12-30 | PHASE2 |
| NCT05985161 | RECRUITING | Wilms Tumor; Rhabdoid Tumor; Malignant Peripheral Nerve Sheath Tumors; MPNST; Nephroblastoma; XPO1 Gene Mutation; Solid Tumor |
Memorial Sloan Kettering Cancer Center |
2023-08-01 | PHASE2 |
| NCT07011056 | RECRUITING | Recurrent and Refractory Diffuse Large B-cell Lymphoma |
Chengdu Zenitar Biomedical Technology Co., Ltd |
2025-07-18 | PHASE3 |
| NCT07200102 | RECRUITING | Multiple Myeloma |
Washington University School of Medicine |
2026-03-17 | PHASE1 |
| NCT07579234 | RECRUITING | Relapsed or Refractory Multiple Myeloma (RRMM) |
Shandong New Time Pharmaceutical Co., LTD |
2026-01-25 | PHASE3 |
| NCT07002099 | RECRUITING | Lymphomas |
Second Affiliated Hospital of Soochow University |
2025-06-01 | PHASE2 |
| NCT06552559 | RECRUITING | B-cell Lymphoma Recurrent; B-cell Lymphoma Refractory; CNS Metastases |
Samsung Medical Center |
2024-05-01 | PHASE1; PHASE2 |
| NCT07569757 | NOT_YET_RECRUITING | Multiple Myeloma |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2026-06 | PHASE3 |
| NCT07779031 | ACTIVE_NOT_RECRUITING | Acute Myeloid Leukaemia (AML); MDS (Myelodysplastic Syndrome) |
Liping Dou |
2025-05-01 | PHASE1; PHASE2 |
| NCT07523737 | RECRUITING | Primary Central Nervous System Lymphoma (PCNSL); Diffuse Large B Cell Lymphoma (DLBCL) |
Beijing Tongren Hospital |
2026-04-01 | PHASE2 |
| NCT05530421 | RECRUITING | Relapsed and Refractory Multiple Myeloma |
University of Miami |
2023-03-26 | PHASE2 |
| NCT07574528 | NOT_YET_RECRUITING | NKTCL |
Sun Yat-sen University |
2026-05-06 | PHASE2 |
| NCT06813079 | RECRUITING | Pancreatic Ductal Carcinoma; Advanced Cancer; Epithelial Tumor |
University Health Network, Toronto |
2025-04-07 | PHASE2 |
| NCT07743957 | NOT_YET_RECRUITING | Light-chain Cardiac Amyloidosis |
Beijing Anzhen Hospital |
2026-07-13 | PHASE2 |
| NCT06265545 | RECRUITING | AML; Refractory; Relapsed |
Institute of Hematology & Blood Diseases Hospital, China |
2024-02-22 | |
| NCT06744894 | NOT_YET_RECRUITING | Multiple Myeloma |
Navy General Hospital, Beijing |
2025-01-01 | PHASE2 |
| NCT07706959 | NOT_YET_RECRUITING | Peripheral T-cell Lymphoma (PTCL) |
Ruijin Hospital |
2026-07 | PHASE1; PHASE2 |
| NCT04414475 | RECRUITING | Multiple Myeloma, Refractory |
Karyopharm Therapeutics Inc |
2020-07-01 | PHASE2 |
| NCT07554482 | NOT_YET_RECRUITING | Extranodal NK/T-cell Lymphoma |
Beijing Tongren Hospital |
2026-05-15 | PHASE2 |
| NCT07437170 | ACTIVE_NOT_RECRUITING | Acute Myeloid Leukemia; Pediatric Acute Myeloid Leukemia; NUP98 Fusion-positive Acute Myeloid Leukemia |
The Children's Hospital of Zhejiang University School of Medicine |
2024-01-01 | PHASE2 |
| NCT07405255 | NOT_YET_RECRUITING | Central Nervous System Lymphoma |
Ruijin Hospital |
2026-01-30 | PHASE2 |
| NCT07138209 | RECRUITING | Relapsed or Refractory Multiple Myeloma |
Qilu Pharmaceutical Co., Ltd. |
2025-11-07 | PHASE3 |
| NCT06158841 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
AbbVie |
2024-05-19 | PHASE3 |
| NCT07172412 | NOT_YET_RECRUITING | Extensive Stage Lung Small Cell Cancer |
Tianjin Medical University Cancer Institute and Hospital |
2025-11 | PHASE2 |
| NCT03147885 | ACTIVE_NOT_RECRUITING | Diffuse Large B-Cell Lymphoma; Recurrent B-Cell Non-Hodgkin Lymphoma; Recurrent Extranodal Marginal Zone Lymphoma; Recurrent Follicular Lymphoma; Recurrent Indolent Adult Non-Hodgkin Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Waldenstrom Macroglobulinemia; Refractory B-Cell Non-Hodgkin Lymphoma; Refractory Extranodal Marginal Zone Lymphoma; Refractory Follicular Lymphoma; Refractory Mantle Cell Lymphoma; Stage III Non-Hodgkin Lymphoma; Stage IV Non-Hodgkin Lymphoma; Transformed Recurrent Non-Hodgkin Lymphoma |
Barbara Ann Karmanos Cancer Institute |
2017-06-20 | PHASE1; PHASE2 |
| NCT05035745 | RECRUITING | Advanced Refractory Solid Tumors; Advanced Triple Negative Breast Cancers; Metastatic Triple Negative Breast Cancers |
National University Hospital, Singapore |
2021-03-01 | PHASE1; PHASE2 |
| NCT07632170 | NOT_YET_RECRUITING | Myeloid Tumors |
Bing Han |
2026-11-01 | |
| NCT06613035 | NOT_YET_RECRUITING | Acute Myeloid Leukemia |
Institute of Hematology & Blood Diseases Hospital, China |
2024-09-30 | PHASE3 |
| NCT07191431 | RECRUITING | Lymphoma Cns |
Ruijin Hospital |
2025-09-22 | |
| NCT07204041 | ACTIVE_NOT_RECRUITING | Langerhans Cell Histiocytosis (LCH) |
Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
2025-08-01 | PHASE2 |
| NCT06573138 | NOT_YET_RECRUITING | Lymphoma, Extranodal NK-T-Cell |
Ruijin Hospital |
2024-09-01 | PHASE2 |
| NCT06573151 | NOT_YET_RECRUITING | Lymphoma |
Ruijin Hospital |
2024-09-01 | PHASE2 |
| NCT07479979 | RECRUITING | Relapse Multiple Myeloma; Refractory Multiple Myeloma |
Natalie Callander |
2026-05-21 | PHASE1; PHASE2 |
| NCT07094464 | ACTIVE_NOT_RECRUITING | TP53-mutated MDS and AML; Allogeneic Hematopoietic Stem Cell Transplantation |
Daihong Liu |
2025-06-01 | PHASE1 |
| NCT05099003 | RECRUITING | Malignant Glioma |
National Cancer Institute (NCI) |
2022-05-31 | PHASE1; PHASE2 |
| NCT05432804 | RECRUITING | Recurrent Glioblastoma, IDH-Wildtype; Recurrent MGMT-Methylated Glioblastoma |
National Cancer Institute (NCI) |
2023-03-20 | PHASE1; PHASE2 |
| NCT05980806 | RECRUITING | Myelofibrosis; Moderate Thrombocytopenia; Mild Thrombocytopenia |
Karyopharm Therapeutics Inc |
2024-04-22 | PHASE2 |
| NCT06966154 | RECRUITING | Natural Killer/T-cell Lymphoma; Relapsed or Refractory Lymphoma Including ENKL |
Fudan University |
2025-05-26 | PHASE1; PHASE2 |
| NCT05333458 | RECRUITING | Advanced Alveolar Soft Part Sarcoma; Advanced Soft Tissue Sarcoma; Metastatic Alveolar Soft Part Sarcoma; Refractory Alveolar Soft Part Sarcoma; Unresectable Alveolar Soft Part Sarcoma |
National Cancer Institute (NCI) |
2022-08-29 | PHASE2 |
| NCT02835222 | ACTIVE_NOT_RECRUITING | Untreated Adult Acute Myeloid Leukemia |
Wake Forest University Health Sciences |
2018-02-02 | PHASE2 |
| NCT06225310 | RECRUITING | Multiple Myeloma in Relapse; Multiple Myeloma, Refractory |
Oncotherapeutics |
2024-08-06 | PHASE1 |
| NCT02343042 | RECRUITING | Multiple Myeloma |
Karyopharm Therapeutics Inc |
2015-10 | PHASE1; PHASE2 |
| NCT04661137 | SUSPENDED | Multiple Myeloma |
Hackensack Meridian Health |
2021-03-16 | PHASE2 |
| NCT05820763 | WITHDRAWN | Multiple Myeloma; Myeloma-Associated Amyloidosis |
Washington University School of Medicine |
2024-01-05 | PHASE2 |
| NCT07369739 | RECRUITING | Lymphohistiocytosis; EBV; CAEBV |
Beijing Friendship Hospital |
2026-01-01 | PHASE2; PHASE3 |
| NCT06517511 | RECRUITING | Diffuse Large B Cell Lymphoma |
Sun Yat-sen University |
2024-08-01 | PHASE2 |
| NCT02436707 | ACTIVE_NOT_RECRUITING | Lymphoma |
Canadian Cancer Trials Group |
2015-10-27 | PHASE2 |
| NCT06822972 | RECRUITING | Multiple Myeloma in Relapse; Multiple Myeloma, Refractory |
Duke University |
2025-08-22 | PHASE2 |
| NCT06559553 | RECRUITING | NKTCL; Selinexor |
Mingzhi Zhang |
2024-09-01 | PHASE1; PHASE2 |
| NCT04442022 | ACTIVE_NOT_RECRUITING | Relapsed/Refractory Diffuse Large B-cell Lymphoma |
Karyopharm Therapeutics Inc |
2020-09-03 | PHASE2; PHASE3 |
| NCT02227251 | ACTIVE_NOT_RECRUITING | Diffuse Large B-cell Lymphoma |
Karyopharm Therapeutics Inc |
2014-11 | PHASE2 |
| NCT06652139 | NOT_YET_RECRUITING | Diffuse Large B Cell Lymphoma |
Ruijin Hospital |
2024-11-01 | PHASE2 |
| NCT06169215 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
National Cancer Institute (NCI) |
2024-07-23 | PHASE2 |
| NCT04562870 | ACTIVE_NOT_RECRUITING | Myelofibrosis |
Karyopharm Therapeutics Inc |
2021-03-17 | PHASE2 |
| NCT06556199 | RECRUITING | Relapsed/Refractory Primary Central Nervous System Lymphoma |
Second Affiliated Hospital, Zhejiang University, School of Medicine |
2024-08-31 | PHASE1; PHASE2 |
| NCT07626021 | NOT_YET_RECRUITING | Myeloproliferative Neoplasms |
Zhongshan Hospital (Xiamen), Fudan University |
2026-07-01 | PHASE2 |
| NCT05900882 | COMPLETED | Multiple Myeloma |
The First Affiliated Hospital with Nanjing Medical University |
2022-07-15 | PHASE2 |
| NCT05611931 | ACTIVE_NOT_RECRUITING | Endometrial Cancer |
Karyopharm Therapeutics Inc |
2023-04-18 | PHASE3 |
| NCT03589222 | ACTIVE_NOT_RECRUITING | Refractory Multiple Myeloma |
PETHEMA Foundation |
2018-07-15 | PHASE2 |
| NCT05675813 | RECRUITING | Peripheral T Cell Lymphoma |
Ruijin Hospital |
2023-02-13 | PHASE1; PHASE2 |
| NCT06853678 | RECRUITING | Extensive Stage Small Cell Lung Cancer (ES-SCLC) |
Tianjin Medical University Cancer Institute and Hospital |
2025-02-28 | |
| NCT05698147 | RECRUITING | Central Nervous System Lymphoma |
Tong Chen, MD |
2023-08-03 | PHASE1; PHASE2 |
| NCT04782687 | ACTIVE_NOT_RECRUITING | Multiple Myeloma; Myeloma Multiple; Kahler Disease; Myeloma, Plasma Cell; Myeloma-Multiple; Myelomatosis; Plasma Cell Myeloma |
US Oncology Research |
2021-09-10 | PHASE2 |
| NCT06114004 | RECRUITING | Sarcoma,Soft Tissue |
Asociación Europea y Latinoamericana SELNET para la Investigación en Sarcomas |
2023-09-28 | PHASE2 |
| NCT07236931 | COMPLETED | AML (Acute Myeloid Leukemia) |
Donghua Zhang |
2025-01-01 | |
| NCT04764942 | ACTIVE_NOT_RECRUITING | Recurrent Multiple Myeloma; Refractory Multiple Myeloma |
Mayo Clinic |
2021-05-06 | PHASE1; PHASE2 |
| NCT05028348 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
European Myeloma Network B.V. |
2022-04-19 | PHASE3 |
| NCT04562389 | ACTIVE_NOT_RECRUITING | Myelofibrosis |
Karyopharm Therapeutics Inc |
2021-03-11 | PHASE3 |
| NCT06765928 | NOT_YET_RECRUITING | MDS; AML, Adult |
Ruijin Hospital |
2025-01-01 | PHASE2 |
| NCT05833893 | RECRUITING | nk/T-cell Lymphoma; Newly Diagnosed; Advanced Lymphoma |
Chinese PLA General Hospital |
2023-05-01 | PHASE2 |
| NCT04425070 | TERMINATED | Peripheral T-cell Lymphoma; NK/T-cell Lymphoma |
Antengene Corporation |
2020-08-18 | PHASE1; PHASE2 |
| NCT04941937 | UNKNOWN | Multiple Myeloma |
Juan Du |
2022-01-27 | PHASE2 |
| NCT04607772 | WITHDRAWN | Relapsed or Refractory Diffuse Large B-Cell Lymphoma |
Karyopharm Therapeutics Inc |
2020-11-18 | PHASE1; PHASE2 |
| NCT04595994 | UNKNOWN | Sarcoma,Soft Tissue |
Grupo Espanol de Investigacion en Sarcomas |
2020-09-02 | PHASE1 |
| NCT04640779 | COMPLETED | Recurrent Histiocytic and Dendritic Cell Neoplasm; Recurrent Hodgkin Lymphoma; Recurrent Non-Hodgkin Lymphoma; Recurrent Plasma Cell Myeloma; Refractory Histiocytic and Dendritic Cell Neoplasm; Refractory Hodgkin Lymphoma; Refractory Non-Hodgkin Lymphoma; Refractory Plasma Cell Myeloma |
Mayo Clinic |
2021-02-08 | PHASE1 |
| NCT06900088 | NOT_YET_RECRUITING | Acute Myeloid Leukemia; Myelodysplastic Syndrome; Chronic Myelomonocytic Leukemia |
Institute of Hematology & Blood Diseases Hospital, China |
2025-04-25 | PHASE2 |
| NCT02199665 | COMPLETED | Refractory Multiple Myeloma |
University of Chicago |
2014-06-12 | PHASE1 |
| NCT06664970 | ENROLLING_BY_INVITATION | MDS |
Peking Union Medical College Hospital |
2024-11-06 | PHASE2 |
| NCT05952687 | WITHDRAWN | Rhabdoid Tumor; Atypical Teratoid/Rhabdoid Tumor; Atypical Teratoid/Rhabdoid Tumor of CNS; CNS Tumor |
St. Jude Children's Research Hospital |
2024-03 | PHASE1 |
| NCT04717700 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
Ida Bruun Kristensen |
2021-08-18 | PHASE2 |
| NCT05498636 | UNKNOWN | DLBCL |
The Affiliated Hospital of Qingdao University |
2022-10-01 | PHASE1; PHASE2 |
| NCT05422066 | UNKNOWN | DLBCL Germinal Center B-Cell Type |
Li Zhiming |
2022-07-26 | PHASE2 |
| NCT05422027 | UNKNOWN | Multiple Myeloma |
Xia Zhongjun |
2022-07-25 | PHASE1; PHASE2 |
| NCT04811196 | COMPLETED | Soft Tissue Sarcoma; Malignant Peripheral Nerve Sheath Tumor (MPNST); Leiomyosarcoma; Endometrial Stromal Sarcoma |
University Health Network, Toronto |
2021-03-29 | PHASE1 |
| NCT05969158 | UNKNOWN | Chemotherapy-Induced Thrombocytopenia |
Sun Yat-sen University |
2023-09-04 | PHASE2 |
| NCT06449482 | TERMINATED | Acute Myeloid Leukemia, Adult |
Institute of Hematology & Blood Diseases Hospital, China |
2023-05-05 | PHASE1; PHASE2 |
| NCT05736965 | RECRUITING | AML, Adult |
Shanghai Tong Ren Hospital |
2023-02-20 | PHASE2 |
| NCT04850755 | COMPLETED | Advance Solid Malignancies; Metastatic Solid Malignancies |
National University Hospital, Singapore |
2021-03-08 | PHASE1 |
| NCT05675319 | TERMINATED | Multiple Myeloma |
Universitätsklinikum Hamburg-Eppendorf |
2023-03-03 | PHASE3 |
| NCT05736978 | RECRUITING | AML; MRD |
Shanghai Tong Ren Hospital |
2023-03-31 | PHASE2 |
| NCT05822050 | UNKNOWN | PTCL Patients Who Achieved Complete Response From Frontline Treatment |
The First Hospital of Jilin University |
2023-06-01 | PHASE2; PHASE3 |
| NCT05577364 | UNKNOWN | EBV-Positive Diffuse Large B-Cell Lymphoma, Nos |
Sun Yat-sen University |
2022-11-01 | PHASE1; PHASE2 |
| NCT03732703 | COMPLETED | Relapsed Refractory Multiple Myeloma |
Multiple Myeloma Research Consortium |
2019-04-01 | PHASE1; PHASE2 |
| NCT04877275 | UNKNOWN | Multiple Myeloma |
Chunyan Sun, MD |
2021-05-21 | PHASE2 |
| NCT04891744 | UNKNOWN | Multiple Myeloma |
Li Zheng |
2021-07-06 | PHASE1; PHASE2 |
| NCT05726110 | RECRUITING | Relapsed or Refractory Acute Myeloid Leukemia |
Shanxi Bethune Hospital |
2023-01-29 | PHASE3 |
| NCT05597345 | RECRUITING | Smoldering Multiple Myeloma |
University of Rochester |
2023-08-21 | PHASE2 |
| NCT04756401 | ACTIVE_NOT_RECRUITING | Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma |
Academic and Community Cancer Research United |
2022-12-08 | PHASE2 |
| NCT02419495 | TERMINATED | Advanced Malignant Solid Neoplasm; Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Fallopian Tube Carcinoma; Metastatic Lung Non-Small Cell Carcinoma; Metastatic Malignant Solid Neoplasm; Metastatic Melanoma; Metastatic Renal Cell Carcinoma; Ovarian Carcinoma; Pathologic Stage III Cutaneous Melanoma AJCC v8; Pathologic Stage IIIA Cutaneous Melanoma AJCC v8; Pathologic Stage IIIB Cutaneous Melanoma AJCC v8; Pathologic Stage IIIC Cutaneous Melanoma AJCC v8; Pathologic Stage IIID Cutaneous Melanoma AJCC v8; Pathologic Stage IV Cutaneous Melanoma AJCC v8; Primary Peritoneal Carcinoma; Stage III Lung Cancer AJCC v8; Stage III Renal Cell Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8; Triple-Negative Breast Carcinoma; Unresectable Lung Non-Small Cell Carcinoma; Unresectable Melanoma; Unresectable Renal Cell Carcinoma |
M.D. Anderson Cancer Center |
2015-06-26 | PHASE1 |
| NCT03955783 | COMPLETED | Diffuse Large B-cell Lymphoma; Acute Myeloid Leukemia; Non-Hodgkin's Lymphoma |
Sanjay Mohan |
2019-06-21 | PHASE1 |
| NCT05951855 | UNKNOWN | Acute Myeloid Leukemia (Relapsed/Refractory) |
The First Affiliated Hospital of Soochow University |
2023-03-01 | PHASE2 |
| NCT04939142 | COMPLETED | Relapsed or Refractory Multiple Myeloma |
Antengene Corporation |
2021-07-12 | PHASE3 |
| NCT04925193 | ACTIVE_NOT_RECRUITING | Multiple Myeloma in Relapse |
University of Colorado, Denver |
2021-11-18 | PHASE2 |
| NCT04256707 | COMPLETED | Non-Small Cell Lung Carcinoma (NSCLC); Colorectal Cancer (CRC); Other Solid Tumors |
Karyopharm Therapeutics Inc |
2020-01-14 | PHASE1; PHASE2 |
| NCT05478993 | UNKNOWN | Multiple Myeloma |
Peking University People's Hospital |
2022-10-12 | PHASE2 |
| NCT05805072 | UNKNOWN | Relapsed/Refractory AML |
The First Affiliated Hospital of Soochow University |
2023-05-01 | |
| NCT06062641 | NOT_YET_RECRUITING | Relapsed or Refractory B-cell Lymphoma |
Ruijin Hospital |
2023-10-30 | PHASE2 |
| NCT05786989 | UNKNOWN | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified |
Chongqing University Cancer Hospital |
2023-02-28 | PHASE4 |
| NCT05952687 | Withdrawn | Rhabdoid Tumor|Atypical Teratoid/Rhabdoid Tumor|Atypical Teratoid/Rhabdoid Tumor of CNS|CNS Tumor |
St. Jude Children''s Research Hospital |
2024-03 | Phase 1 |
| NCT05322330 | COMPLETED | Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma |
The First Affiliated Hospital of Soochow University |
2022-02-10 | PHASE2 |
| NCT04856189 | TERMINATED | Advanced Urothelial Carcinoma; Locally Advanced Urothelial Carcinoma; Metastatic Urothelial Carcinoma; Refractory Urothelial Carcinoma |
Mamta Parikh |
2021-04-08 | PHASE1; PHASE2 |
| NCT05974085 | UNKNOWN | Double Hit Lymphoma; Triple Hit Lymphoma |
Zhejiang Cancer Hospital |
2022-08-01 | PHASE2 |
| NCT04519476 | UNKNOWN | Refractory Multiple Myeloma |
Oncotherapeutics |
2020-11-01 | PHASE1 |
| NCT04216329 | ACTIVE_NOT_RECRUITING | Gliosarcoma; Newly Diagnosed; Glioblastoma |
National Cancer Institute (NCI) |
2020-07-07 | PHASE1 |
| NCT04768881 | TERMINATED | Locally Advanced Unresectable or Metastatic Melanoma |
Karyopharm Therapeutics Inc |
2021-05-12 | PHASE2 |
| NCT05975944 | UNKNOWN | Extensive-stage Small Cell Lung Cancer |
Tianjin Medical University Cancer Institute and Hospital |
2023-09 | PHASE1; PHASE2 |
| NCT03627403 | TERMINATED | Primary Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis; Post-polycythemia Vera Myelofibrosis |
University of Utah |
2019-05-10 | PHASE2 |
| NCT05698147 | Recruiting | Central Nervous System Lymphoma |
Tong Chen|Antengene Corporation|Huashan Hospital |
2023-08-03 | Phase 1|Phase 2 |
| NCT04898894 | ACTIVE_NOT_RECRUITING | Acute Leukemia of Ambiguous Lineage in Relapse; Acute Myeloid Leukemia, in Relapse; Refractory Acute Leukemia of Ambiguous Lineage; Refractory Acute Myeloid Leukemia |
St. Jude Children's Research Hospital |
2021-11-15 | PHASE1 |
| NCT04421378 | TERMINATED | Glioblastoma Multiforme |
Karyopharm Therapeutics Inc |
2020-06-08 | PHASE1; PHASE2 |
| NCT02069730 | COMPLETED | Salivary Gland Cancer; Metastatic; Advanced; Recurrent |
University Health Network, Toronto |
2014-06 | |
| NCT05954780 | Recruiting | Multiple Myeloma |
iOMEDICO AG|Stemline Switzerland GmbH|Climedo Health GmbH |
2023-06-28 | -- |
| NCT04984330 | WITHDRAWN | Amyloid; Amyloidosis; AL Amyloidosis |
Weill Medical College of Cornell University |
2021-12 | EARLY_PHASE1 |
| NCT04138381 | UNKNOWN | Maximum Tolerated Dose; GIST; Metastatic Adult Soft Tissue Sarcoma; Drug Toxicity; Drug Use |
Grupo Espanol de Investigacion en Sarcomas |
2019-08-16 | PHASE1; PHASE2 |
| NCT05201118 | UNKNOWN | Extramedullary Multiple Myeloma |
Chunrui Li |
2022-01-01 | PHASE1 |
| NCT04843579 | TERMINATED | Myeloma Multiple; Myeloma; Refractory Multiple Myeloma |
Weill Medical College of Cornell University |
2021-12-29 | PHASE2 |
| NCT04534725 | COMPLETED | Cancer; Covid19; Respiratory Viral Infection |
Peter MacCallum Cancer Centre, Australia |
2020-12-17 | PHASE3 |
| NCT03095612 | TERMINATED | Non-small Cell Lung Cancer |
University of Texas Southwestern Medical Center |
2018-03-22 | PHASE1; PHASE2 |
| NCT06212596 | COMPLETED | Relapsed or Refractory Multiple Myeloma |
University of Leeds |
2018-07-16 | PHASE2 |
| NCT05093608 | TERMINATED | Hepatocellular Carcinoma |
H. Lee Moffitt Cancer Center and Research Institute |
2021-11-03 | PHASE1 |
| NCT02323880 | COMPLETED | Malignant Glioma; Recurrent Brain Neoplasm; Recurrent Childhood Central Nervous System Neoplasm; Recurrent Childhood Glioblastoma; Recurrent Lymphoma; Recurrent Malignant Solid Neoplasm; Refractory Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Primary Central Nervous System Neoplasm; WHO Grade 3 Glioma |
Children's Oncology Group |
2015-10-30 | PHASE1 |
| NCT04854434 | TERMINATED | Metastatic Colorectal Cancer |
Karyopharm Therapeutics Inc |
2021-06-29 | PHASE2 |
| NCT05170789 | WITHDRAWN | Relapsed Multiple Myeloma; Refractory Multiple Myeloma |
Tulane University School of Medicine |
2022-04-27 | PHASE2 |
| NCT02303392 | COMPLETED | Prolymphocytic Leukemia; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia |
Jennifer Woyach |
2015-06-09 | PHASE1 |
| NCT05170789 | Withdrawn | Relapsed Multiple Myeloma|Refractory Multiple Myeloma |
Tulane University School of Medicine|Karyopharm Therapeutics Inc|Tulane University |
2022-04-27 | Phase 2 |
| NCT03555422 | COMPLETED | Endometrial Cancer |
Karyopharm Therapeutics Inc |
2018-01-05 | PHASE3 |
| NCT05201118 | Unknown status | Extramedullary Multiple Myeloma |
Chunrui Li|Nanjing IASO Biotechnology Co. Ltd.|Tongji Hospital |
2022-01-01 | Phase 1 |
| NCT02178436 | COMPLETED | Acinar Cell Adenocarcinoma of the Pancreas; Duct Cell Adenocarcinoma of the Pancreas; Stage IV Pancreatic Cancer |
Mohammed Najeeb Al Hallak |
2014-10-31 | PHASE1; PHASE2 |
| NCT02741388 | COMPLETED | B-cell Lymphoma |
The Lymphoma Academic Research Organisation |
2016-10 | PHASE1 |
| NCT02269293 | COMPLETED | Ovarian Cancer; Endometrial Cancer |
Memorial Sloan Kettering Cancer Center |
2014-10-13 | PHASE1 |
| NCT02228525 | COMPLETED | Myelodysplastic Syndromes |
Memorial Sloan Kettering Cancer Center |
2014-08-27 | PHASE2 |
| NCT02780609 | COMPLETED | Multiple Myeloma |
H. Lee Moffitt Cancer Center and Research Institute |
2017-07-20 | PHASE1; PHASE2 |
| NCT03880123 | WITHDRAWN | Liposarcoma; Malignant Peripheral Nerve Sheath Tumors; Alveolar Soft Part Sarcoma; Ewing Sarcoma; Sarcoma |
Matthew Ingham |
2020-11 | PHASE1 |
| NCT02831686 | COMPLETED | Multiple Myeloma; Relapsed and/or Refractory Multiple Myeloma |
Memorial Sloan Kettering Cancer Center |
2016-07 | PHASE1 |
| NCT03212937 | COMPLETED | Peripheral T-cell Lymphoma |
National Cancer Centre, Singapore |
2016-07-01 | PHASE1 |
| NCT02606461 | COMPLETED | Dedifferentiated Liposarcoma |
Karyopharm Therapeutics Inc |
2016-01-04 | PHASE2; PHASE3 |
| NCT04349098 | COMPLETED | Coronavirus Infection |
Karyopharm Therapeutics Inc |
2020-04-17 | PHASE2 |
| NCT04355676 | WITHDRAWN | Coronavirus Infection |
Karyopharm Therapeutics Inc |
2020-04-30 | PHASE2 |
| NCT03193437 | TERMINATED | Thymoma; Advanced Thymic Epithelial Tumor |
Georgetown University |
2018-04-03 | PHASE2 |
| NCT03466827 | UNKNOWN | Thymoma; Advanced Thymic Epithelial Tumour |
Morten Mau-Soerensen |
2017-10-12 | PHASE2 |
| NCT02078349 | COMPLETED | Solid Tumors |
National University Hospital, Singapore |
2014-02 | PHASE1 |
| NCT03110562 | COMPLETED | Multiple Myeloma |
Karyopharm Therapeutics Inc |
2017-05-24 | PHASE3 |
| NCT01986348 | TERMINATED | Glioblastoma; Glioma |
Karyopharm Therapeutics Inc |
2014-03-03 | PHASE2 |
| NCT03042819 | COMPLETED | Soft Tissue Sarcoma |
University Health Network, Toronto |
2017-05-16 | PHASE1 |
| NCT02471911 | COMPLETED | Diffuse Large B-Cell Lymphoma |
Weill Medical College of Cornell University |
2015-12-11 | PHASE1 |
| NCT02336815 | COMPLETED | Multiple Myeloma |
Karyopharm Therapeutics Inc |
2015-05-26 | PHASE2 |
| NCT03661515 | COMPLETED | Acute Myeloid Leukemia |
PETHEMA Foundation |
2018-07-17 | PHASE1 |
| NCT02416908 | COMPLETED | Acute Myeloid Leukemia |
Washington University School of Medicine |
2015-06-16 | PHASE1; PHASE2 |
| NCT03071276 | TERMINATED | Acute Myeloid Leukemia (AML) |
St. Jude Children's Research Hospital |
2016-01-14 | PHASE2 |
| NCT02530476 | COMPLETED | Leukemia; Acute Myeloid Leukemia |
M.D. Anderson Cancer Center |
2015-12-08 | PHASE1; PHASE2 |
| NCT02536495 | WITHDRAWN | Recurrent Squamous Cell Lung Carcinoma; Stage IV Squamous Cell Lung Carcinoma |
Erin Bertino |
2015-09 | PHASE1; PHASE2 |
| NCT02249091 | COMPLETED | Acute Myeloid Leukemia (Relapsed/Refractory) |
GSO Global Clinical Research BV |
2014-09 | PHASE2 |
| NCT02120222 | COMPLETED | Recurrent Melanoma |
Kari Kendra |
2014-08-22 | PHASE1 |
| NCT02299518 | COMPLETED | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Recurrent Adult Acute Myeloid Leukemia; Secondary Acute Myeloid Leukemia |
Alice Mims |
2015-05-18 | PHASE1 |
| NCT02485535 | COMPLETED | Acute Myeloid Leukemia; de Novo Myelodysplastic Syndrome; Myelodysplastic Syndrome; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndrome |
University of Chicago |
2015-09-04 | PHASE1 |
| NCT02091245 | ACTIVE_NOT_RECRUITING | Relapsed Acute Lymphoblastic Leukemia (ALL); Refractory Acute Lymphoblastic Leukemia (ALL); Relapsed Acute Myelogenous Leukemia (AML); Refractory Acute Myelogenous Leukemia (AML); Relapsed Mixed Lineage Leukemia; Refractory Mixed Lineage Leukemia; Relapsed Biphenotypic Leukemia; Refractory Biphenotypic Leukemia; Chronic Myelogenous Leukemia (CML) in Blast Crisis |
Dana-Farber Cancer Institute |
2014-03 | PHASE1 |
| NCT02088541 | COMPLETED | Acute Myeloid Leukemia (AML) |
Karyopharm Therapeutics Inc |
2014-03 | PHASE2 |
| NCT02573363 | COMPLETED | Acute Myeloid Leukemia |
University of Chicago |
2015-10-07 | PHASE1 |
| NCT02389543 | WITHDRAWN | Multiple Myeloma |
Karyopharm Therapeutics Inc |
2015-07 | PHASE1; PHASE2 |
| NCT02431351 | WITHDRAWN | Myelodysplastic Syndrome |
Karyopharm Therapeutics Inc |
2015-11 | PHASE2 |
| NCT02186834 | COMPLETED | Multiple Myeloma |
H. Lee Moffitt Cancer Center and Research Institute |
2014-09-23 | PHASE1; PHASE2 |
| NCT02628704 | WITHDRAWN | Multiple Myeloma |
Karyopharm Therapeutics Inc |
2015-12 | PHASE2 |
| NCT02137356 | UNKNOWN | Rectal Neoplasms |
Sheba Medical Center |
2014-12 | PHASE1 |
| NCT02384850 | TERMINATED | Colorectal Neoplasm |
GSO Global Clinical Research BV |
2015-03 | PHASE1 |
| NCT02215161 | TERMINATED | Castration Levels of Testosterone; Hormone-Resistant Prostate Cancer; Metastatic Prostate Carcinoma in the Soft Tissue; Prostate Carcinoma Metastatic in the Bone; PSA Progression; Stage IV Prostate Adenocarcinoma AJCC v7 |
University of California, San Francisco |
2014-09-02 | PHASE2 |
| NCT02025985 | COMPLETED | Ovarian Carcinoma; Endometrial Carcinoma; Cervical Carcinoma |
Karyopharm Therapeutics Inc |
2014-04-09 | PHASE2 |
| NCT02093403 | COMPLETED | Acute Myeloid Leukemia; Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia |
Bhavana Bhatnagar |
2014-03 | PHASE1 |
| NCT01896505 | COMPLETED | Sarcoma |
Karyopharm Therapeutics Inc |
2013-07-30 | PHASE1 |
| NCT02403310 | COMPLETED | Leukemia; Acute Myeloid Leukemia; AML |
H. Lee Moffitt Cancer Center and Research Institute |
2015-06-18 | PHASE1 |
| NCT02138786 | TERMINATED | Richter's Transformation |
Karyopharm Therapeutics Inc |
2014-11-14 | PHASE2 |
| NCT02250885 | COMPLETED | Carcinoma, Neuroendocrine |
Gabrail Cancer Center Research |
2014-08 | PHASE2 |
| NCT02146833 | TERMINATED | Prostate Cancer |
Karyopharm Therapeutics Inc |
2014-05 | PHASE2 |
| NCT01607905 | COMPLETED | Solid Tumor |
Karyopharm Therapeutics Inc |
2012-06-18 | PHASE1 |
| NCT02402764 | COMPLETED | Breast Cancer |
H. Lee Moffitt Cancer Center and Research Institute |
2015-07-08 | PHASE2 |
| NCT02314247 | TERMINATED | Peripheral T-cell Lymphoma (PTCL); Cutaneous T-cell Lymphoma (CTCL) |
Karyopharm Therapeutics Inc |
2015-02 | PHASE2 |
| NCT02213133 | TERMINATED | Squamous Cell Carcinoma |
Karyopharm Therapeutics Inc |
2014-09-22 | PHASE2 |
| NCT02212561 | COMPLETED | Acute Myeloid Leukemia (AML); Acute Lymphoblastic Leukemia (ALL); Myelodysplastic Syndrome (MDS); Mixed Phenotype Acute Leukemia (MPAL) |
St. Jude Children's Research Hospital |
2014-08 | PHASE1 |
| NCT02283359 | TERMINATED | Esophageal Cancer; Gastric Cancer |
H. Lee Moffitt Cancer Center and Research Institute |
2014-12 | PHASE1 |
| NCT02351505 | TERMINATED | Recurrent Small Cell Lung Carcinoma |
Erin Bertino |
2015-05 | PHASE2 |
| NCT01607892 | COMPLETED | Hematological Malignancies |
Karyopharm Therapeutics Inc |
2012-07-23 | PHASE1 |
| NCT05177276 | WITHDRAWN | Solid Tumor Malignancy |
Martin Gutierrez |
2014-09 | PHASE1; PHASE2 |
| NCT02367690 | WITHDRAWN | Diabetic Foot Ulcers |
Karyopharm Therapeutics Inc |
2015-01 | PHASE1; PHASE2 |
(data from https://clinicaltrials.gov, updated on 2026-08-03)
Check the
Selinexor (KPT-330)
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
- Selinexor (KPT-330) Mechanism of Action: XPO1 Inhibition in Plasma Cell Research
- Selinexor (KPT-330) Working Concentration | Cell Culture | Treatment
- Selinexor (KPT-330) Solubility in DMSO
- Selinexor (KPT-330) Stock Solution
- Selinexor (KPT-330) Storage
- Selinexor (KPT-330) Stability
- Selinexor (KPT-330) Combination Database
- Selinexor (KPT-330) Molecular Weight
- Selinexor (KPT-330) SMILES
- Selinexor (KPT-330) CAS Number
- Selinexor (KPT-330) Chemical Structure (2D and 3D)
- Selinexor (KPT-330) IC50 for Cell-based and Cell-free Assays
- Selinexor (KPT-330) Sigma (AMBH2D6FBC43)? Try a better option.
- Selinexor (KPT-330) Tocris (7760)? Try a better option.
- Selinexor (KPT-330) MedChemExpress (HY-17536)? Try a better option.
- Selinexor (KPT-330) Cayman (39562)? Try a better option.
- Selinexor (KPT-330) Abmole (M3152)? Try a better option.
- Selinexor (KPT-330) SDS｜MSDS
Note: Technical data last updated: Sep 1, 2026.